Neurogastrx grabbed $45 million to bring its gastroparesis drug through proof of concept.

Ex-Receptos CEO Faheem Hasnain has been keeping a low profile since selling the company to Celgene, but now he is back at the helm of a new biotech.

The gene therapy sector has a new player—Generation Bio—which promises to provide safer, more controllable treatments that do away with the need to use viruses…

The round positions BioNTech to mount a multifront attack on cancer, spearheaded by mRNA therapies and supported by modalities including CAR-T cells.

The series A positions a team with résumés dotted with senior posts at Serono, Eli Lilly and Novartis to advance multifunctional anticancer drugs.

Boehringer Ingelheim is deepening its venture fund pockets from €100 million to €250 million as it looks to change up its investment strategy.

Just over a year ago Syntimmune announced Boehringer and Pfizer veteran David de Graaf, Ph.D., as its new CEO. Now he’s out the door.

The series C tees up Scholar Rock to find out whether its myostatin blocker can best one-time rivals from companies including Novartis.